PYLARIFY AI™ is a deep learning application that enables accurate, efficient, and reproducible quantification of PSMA PET/CT scans.
PYLARIFY AI™ is the only FDA-cleared medical device to offer standardized quantitative and accurate reporting of PSMA PET/CT images. Standardized reporting of PSMA assessments can improve the management of prostate cancer patients, including the accurate quantification of disease burden with increased reproducibility on a patient level.
1. FDA clearance letter for aPROMISE. Food and Drug Administration. July 27, 2021.
2. Nickols N, Anand A, Johnsson K, et al. aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer. J Nucl Med. 2021.
3. Johnsson, K., Brynolfsson, J., Sahlstedt, H. et al. Analytical performance of aPROMISE: automated anatomic contextualization, detection, and quantification of [18F]DCFPyL (PSMA) imaging for standardized reporting. Eur J Nucl Med Mol Imaging 49, 1041–1051 (2022). https://doi.org/10.1007/s00259-021-05497-8
©2022 SYNTERMED INC. - ALL RIGHTS RESERVED. | FOR PERMISSION, EMAIL